Publications
419 results found
Salciccioli I, Mariano M, Goodall R, et al., 2022, PRIMARY IMMUNODEFICIENCY DISEASE MORTALITY TRENDS ACROSS EU15+COUNTRIES: AN EPIDEMIOLOGICAL ANALYSIS, Publisher: ELSEVIER SCIENCE INC, Pages: S57-S57, ISSN: 1081-1206
Yang D, Borsky K, Jani C, et al., 2022, Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017, British Journal of Dermatology, ISSN: 0007-0963
Gueroult A, Al-Balah A, Shalhoub J, et al., 2022, Nickel hypersensitivity and endovascular devices: a systematic review and meta-analysis, Heart, Vol: 108, Pages: 1707-1715, ISSN: 1355-6037
Objective Nickel allergy is common; endovascular specialists are often confronted with nickel allergic patients ahead of the implantation of endovascular devices, many of which are nickel-containing. Our aim was to elucidate whether nickel hypersensitivity is significantly associated with worse or adverse outcomes after placement of a nickel-containing endovascular device.Methods Inclusion criteria were: endovascular and transcatheter procedures for coronary, structural heart, neurovascular and peripheral vascular pathology involving nickel-allergic patients. All adverse outcomes were included as defined by included studies. A systematic review and meta-analysis were undertaken using a random-effects model. Searches of MEDLINE and EMBASE were conducted for articles published 1947–2019.Results 190 records were identified, 78 articles were included for qualitative synthesis and 15 met criteria for meta-analysis. Patch-test confirmed nickel allergy was associated with an increased risk of adverse outcomes following implantation of a nickel-containing endovascular device (n=14 articles, 1740 patients; OR 2.61, 95% CI 1.41 to 4.85). This finding further was observed in coronary (n=12 articles, 1624 patients; OR 1.94, 95% CI 1.16 to 3.23) and structural heart subgroups (n=2 articles, 83 patients; OR 52.28, 95% CI 1.31 to 2079.14), but not in the neurovascular subgroup (n=1 article, 33 patients; OR 3.04, 95% CI 0.59 to 15.72) or with a patient-reported history of nickel allergy (n=2 articles, 207 patients; OR 2.14, 95% CI 0.23 to 19.70).Conclusions Patch-tested nickel allergy is associated with an increased risk of adverse outcomes following endovascular device implantation and alternative treatment options should be considered. Specialists faced with patients’ self-reporting nickel allergy should consider proceeding to diagnostic patch-testing.
Benson R, Nandhra S, The VERN COVER Collaborative, et al., 2022, Recovery of vascular services and adaptation of clinical practice in Europe following the initial COVID-19 pandemic peak, EJVES Vascular Forum
Ambler G, Hitchman L, Benson R, et al., 2022, Comment on: Collaborative research: population-based data and validation are necessary, British Journal of Surgery, Vol: 109, Pages: e111-e112, ISSN: 0007-1323
Hartley A, Owen S, Caga-Anan M, et al., 2022, The ex vivo on-ECMO amputated human limb model of atherosclerosis, Publisher: OXFORD UNIV PRESS, Pages: 3041-3041, ISSN: 0195-668X
Ojha U, Marshall D, Salciccioll J, et al., 2022, An observational analysis of trends in rheumatic heart disease incidence and mortality in EU15+countries over 29 years, Publisher: OXFORD UNIV PRESS, Pages: 2237-2237, ISSN: 0195-668X
The Vascular and Endovascular Research Network VERN COVER Study Collaborative, Shalhoub J, 2022, The impact of the COronaVIrus Disease 2019 (COVID-19) pandemic on the clinical management of patients with vascular diseases - Findings from Tier 3 of the COVID-19 Vascular sERvice (COVER) Study, Journal of the Vascular Societies Great Britain and Ireland
Eves J, Sudarsanam A, Shalhoub J, et al., 2022, Augmented reality in vascular and endovascular surgery: a scoping review, JMIR Serious Games, Vol: 10, ISSN: 2291-9279
Background: Technological advances have transformed vascular intervention over recent decades. In particular, improvements in imaging and data processing have allowed for the development of increasingly complex endovascular and hybrid interventions. Augmented reality (AR) is a subject of growing interest within surgery, with potential to improve clinicians’ understanding of 3D anatomy and aid the processing of real-time information. This paper hopes to elucidate the potential impact of AR technology in the rapidly evolving field of vascular and endovascular surgery.Objective: The aim of this review was to summarise the fundamental concepts of augmented reality technologies, and to conduct a scoping review of the impact of AR and mixed reality within vascular and endovascular surgery.Methods: A systematic search of MEDLINE, Scopus and Embase was performed in accordance with the Preferred Reporting Items on Systematic Reviews and Meta-analysis (PRISMA) guidelines. All studies written in English from inception until 8th of January 2021 were included in the search. Combinations of the following keywords were used in the systematic search string: (‘augmented reality’ OR ‘hololens’ OR ‘image overlay’ OR ‘daqri’ OR ‘magic leap’ OR ‘immersive reality’ OR ‘extended reality’ OR ‘mixed reality’ OR ‘head mounted display’) AND (‘vascular surgery’ OR ‘endovascular’). Studies were selected by a blinded process between two investigators and assessed with data quality tools.Results: AR technologies have had a number of applications across vascular and endovascular surgery. The majority of studies use 3D imaging of CT angiogram-derived images of vascular anatomy to augment the clinicians anatomical understanding during procedures. A wide range of AR technologies have been employed, with ‘heads up’ fusion imaging and AR head-mounted disp
Turner B, Machin M, Jasionowska S, et al., 2022, Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions, Annals of Surgery, Vol: 278, Pages: 166-171, ISSN: 0003-4932
Objective: The primary objective of this systematic review and meta-analysis was to elucidate the rate of venous thromboembolism (VTE) following endovenous varicose vein intervention with mechanical thromboprophylaxis and additional pharmacological thromboprophylaxis, versus mechanical thromboprophylaxis alone.Summary Background Data: The VTE rate following endovenous procedures is higher than other day-case procedures and could be reduced with pharmacological thromboprophylaxis.Methods: The review followed PRISMA guidelines with a registered protocol (PROSPERO: CRD42021274963). Studies of endovenous intervention for superficial venous incompetence reporting the predefined outcomes with at least 30 patients were eligible. Data were pooled with a fixed effects model.Results: There were 221 trials included in the review (47 randomised trial arms, 105 prospective cohort studies and 69 retrospective studies). In randomised trial arms, the rate of deep venous thrombosis with additional pharmacological thromboprophylaxis was 0.52% (95% CI 0.23-1.19%) (9 studies; 1095 patients; 2 events), versus 2.26% (95% CI 1.81-2.82%) (38 studies; 6951 patients; 69 events) with mechanical thromboprophylaxis alone. The rate of pulmonary embolism in randomised trial arms with additional pharmacological thromboprophylaxis was 0.45% (95% CI 0.09-2.35) (5 studies, 460 participants, 1 event) versus 0.23% (95% CI 0.1-0.52%) (28 studies, 4834 participants, 3 events) for mechanical measures alone. The rate of EHIT grade III-IV was 0.35% (95% CI 0.09-1.40) versus 0.88% (95% CI 0.28-2.70%). There was one VTE-related mortality and one instance of major bleeding, with low rates of minor bleeding.Conclusions: There is a significant reduction in the rate of DVT with additional pharmacological thromboprophylaxis and routine prescription of anticoagulation following endovenous varicose vein intervention should be considered. VTE risk for individual study participants is heterogeneous and risk stratifica
Ali R, Sugand K, Goodall R, et al., 2022, 12 Trends in Neck of Femur Fracture Incidence in EU15+Countries From 1990-2017, ASiT Surgical Conference, Publisher: OXFORD UNIV PRESS, ISSN: 0007-1323
Lawton R, Hunt B, Norrie J, et al., 2022, Compression Hosiery to Avoid Post-Thrombotic Syndrome (CHAPS) Trial, European Journal of Vascular and Endovascular Surgery, ISSN: 1078-5884
Lawton R, Shalhoub J, Davies A, 2022, Implementation of the graduated compression as an adjunct to pharmaco-thromboprophylaxis in surgery (GAPS) trial results across the UK, Phlebology, Vol: 37, Pages: 540-542, ISSN: 0268-3555
ObjectivesTo examine uptake and dissemination of a National Institute for Health Research (NIHR) Health Technology Assessment (HTA) funded trial- Graduated compression as an Adjunct to Pharmaco-thromboprophylaxis in Surgery (GAPS) (project number: 14/140/61) amongst health professionals in the UK. To evaluate the impact of the trial on venous thromboembolism (VTE) prevention policies 7 months after publication.MethodA 12-question online survey emailed to 2750 individuals via several vascular societies, 34 VTE Exemplar Centre leads and 1 charity over a 3-month period.ResultsIn total, 250 responses were received; a 9.1% response rate. Over half of all respondents (52.4%) had read the GAPS trial results prior to completing the survey. Precisely, 77.1% said their hospital had not yet made changes or did not intend to make changes to local hospital VTE policy based on the GAPS trial.ConclusionsFindings must be interpreted in the context of the low response rate. Further in-depth interviews would aid understanding of barriers to implementing change.
Abdallah N, Mouchati C, Crowley C, et al., 2022, Trends in mortality from aortic dissection analyzed from the World Health Organization Mortality Database from 2000 to 2017, International Journal of Cardiology, Vol: 360, Pages: 83-90, ISSN: 0167-5273
Background:We assessed trends in aortic dissection (AD) death rates in 23 countries from 2000 to 2017.Methods:We extracted AD mortality data for countries with high usability data from the World Health Organization (WHO) Mortality Database and from the Center for Disease Control (CDC) WONDER Database for the United States of America (USA). Age Standardized Death Rates (ASDRs) per 100,000 population were computed. Trends were assessed by locally weighted scatter plot smoother (LOWESS) regression.Results:Between 2000 and 2017, ASDRs from AD decreased in Australia, Belgium, Croatia, Denmark, France, Italy, New Zealand, Norway, Sweden, the United Kingdom, and the USA for both sexes. Increasing AD mortality was observed in Austria, Czech Republic, Germany, Hungary, Israel, and Japan for both sexes. The largest absolute increases in ASDR were in Japan for men (+1.59) and women (+1.11). The largest percentage decreases were in Norway for men (−0.91) and in New Zealand (−0.6) for women. In 2017, the highest mortality rates were in Japan for both sexes (3.22 and 2.09, respectively). The lowest ASDR was in Kyrgyzstan for both sexes (0.16 and 0.10, respectively). ASDRs for AD in 2017 were higher for men than women in all countries included. Spain had the greatest difference between the gender's mortality rates with a 2.71-fold higher mortality average rate in men.Conclusion:We identified an overall decrease in AD mortality in most included countries, while an increase was noted in other countries including Israel and Japan.
Shalhoub J, 2022, Contracting role of graduated compression stockings in prevention of perioperative venous thromboembolism, British Journal of Surgery, Vol: 109, Pages: 669-670, ISSN: 0007-1323
Gwilym B, VERN Collaborators, PERCEIVE Collaborators, et al., 2022, Surgeons and anaesthetists predict 30-day outcomes after major lower limb amputation more accurately than most prediction tools: early results from the PERCEIVE (PrEdiction of Risk and Communication of outcomE following major lower limb amputation: a collaboratIVE) study, British Journal of Surgery, ISSN: 0007-1323
Marshall DC, Al Omari O, Goodall R, et al., 2022, Trends in prevalence, mortality, and disability-adjusted life-years relating to chronic obstructive pulmonary disease in Europe: an observational study of the global burden of disease database, 2001-2019, BMC Pulmonary Medicine, Vol: 22, Pages: 1-11, ISSN: 1471-2466
IntroductionChronic Obstructive Pulmonary Disease (COPD) is associated with significant mortality and well-defined aetiological factors. Previous reports indicate that mortality from COPD is falling worldwide. This study aims to assess the burden of COPD using prevalence, mortality, and disability-adjusted life years (DALYs) between 2001 and 2019 in 28 European countries (the European Union and the United Kingdom).MethodsWe extracted COPD data from the Global Burden of Disease database based on the International Classification of Diseases versions 10 (J41, 42, 43, 44 and 47). Age-standardised prevalence rates (ASPRs), age-standardised mortality rates (ASMRs), and DALYs were analysed for European countries by sex for each year (2001–2019) and reported per 100,000 population. We used Joinpoint regression analysis to quantify changing trends in the burden of COPD.ResultsIn 2019, the median ASPR across Europe was 3230/100,000 for males and 2202/100,000 for females. Between 2001 and 2019, the median percentage change in ASPR was − 9.7% for males and 4.3% for females. 23/28 countries demonstrated a decrease in ASPRs in males, and 11/28 demonstrated a decrease in females. The median percentage change in ASMR between 2001 and 2019 was − 27.5% for males and − 10.4% for females. 25/28 and 19/28 countries demonstrated a decrease in ASMR in males and females, respectively.ConclusionIn the EU between 2001 and 2019 COPD prevalence has overall increased in females but continues to decrease in males and in some countries, female prevalence now exceeds that of males. COPD mortality in the EU has decreased overall between 2001 and 2019; however, this decrease is not universal, particularly in females, and therefore remains a substantial source of amenable mortality.
Roy Choudhury J, Ding A, Onida S, et al., 2022, O074 Metabolic phenotyping in diabetic foot ulceration, Annual Scientific Meeting of the Surgical-Research-Society, Publisher: OXFORD UNIV PRESS, ISSN: 0007-1323
Hanna L, Sounderajah V, Abdullah A, et al., 2022, Trends in thoracic aortic aneurysm hospital admissions, interventions and mortality in England between 1998 to 2020: An observational study, European Journal of Vascular and Endovascular Surgery, ISSN: 1078-5884
Salciccioli J, Marshall D, Goodall R, et al., 2022, Interstitial lung disease incidence and mortality in the United Kingdom and the European Union: an observational study, 2001-2017, ERJ Open Research, Vol: 8, Pages: 1-12, ISSN: 2312-0541
Objective: To compare the trends in age-standardised incidence and mortality from interstitial lung diseases (ILD) in the United Kingdom (UK) and the European Union (EU).Design: Observational study using data obtained from the Global Burden of Disease Study.Setting and Participants: Residents of the UK and of the twenty-seven EU countries.Main outcome measures: ILD age-standardised incidence rates per 100 000 (ASIR), age-standardised death rates per 100 000 (ASDR), and mortality-to-incidence ratio (MIRs) are presented for males and females separately for each country, for the years 2001–2017. Trends were analysed using Joinpoint regression analysis.Results: For men, in 2017, the median incidence of ILD was 7.22 (IQR 5.57–8.96) per 100 000 population. For women, in 2017, the median incidence of ILD was 4.34 (IQR 3.36–6.29) per 100 000 population. For men, in 2017, the median ASDR attributed to ILD was 2.04 (IQR 1.13–2.71) per 100 000 population. For women, the median ASDR in 2017 for ILD was 1.02 (0.68–1.37) per 100 000 population. There was an overall increase in ASDR during the observation period with a median change of +20.42% (IQR 5.44–31.40) for men and an increase of +15.44% (IQR −1.01–31.52) for women. Despite increases in mortality over the entire observation period, there were decreasing mortality trends in the majority of countries at the end of the observation period (75% for men and 86% for women).Conclusion: Over the past two decades, there have been increases in the incidence and mortality of interstitial lung diseases in Europe. The most recent trends, however, demonstrate decreases in mortality from ILD in the majority of European countries for both men and women. These data support the ongoing improvements in the diagnosis and management of ILD.
Stather P, Bearne L, Shalhoub J, et al., 2022, The future of exercise therapy for people with intermittent claudication?, Journal of Vascular Societies Great Britain and Ireland, ISSN: 2754-0030
National Institute for Care Excellence (NICE) guideline 1471 recommends supervised exercise therapy (SET) for all patients with intermittent claudication, consisting of 2 hours of SET per week for a 3 month period. This is supported by good evidence from Cochrane reviews2,3 that SET shows improvement in mean walking performance compared with home based exercise and walking advice, with an increase of 120-210 metres, and also has comparable results to endovascular revascularisation. Despite this evidence and the guidance from NICE the provision of SET is variable, with <50% of UK hospitals providing SET and <25% meeting the NICE dose recommendation4. With centralisation of services into a hub and spoke model, the spokes are likely to have inferior access to SET. Furthermore, attendance and uptake rates to SET are often less than 25%5. Barriers associated with provision and uptake include access, time, travel and pain.
Hanbury GH, Jani C, Abdallah N, et al., 2022, Trends in oncological disease burden: A comparative study between higher and lower-middle-income countries., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Hartley A, Owen S, Caga-Anan M, et al., 2022, FIRST DEMONSTRATION OF A NOVEL EXPERIMENTAL MODEL OF ATHEROSCLEROSIS. THE EX VIVO ON-ECMO AMPUTATED 'LIVING' HUMAN LIMB MODEL, Annual Conference of the British-Cardiovascular-Society - 100 Years of Cardiology, Publisher: BMJ PUBLISHING GROUP, Pages: A152-A152, ISSN: 1355-6037
Singh H, Bhatt P, Agarwal L, et al., 2022, Trends in Pulmonary Hypertension Mortality Between 1999 and 2019: An Observational Study Across the United States, International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Al Omari O, Marshall DC, Salciccioli JD, et al., 2022, Trends in Prevalence, Mortality, and Disability-Adjusted Life-Years Relating to Chronic Obstructive Pulmonary Disease in Europe: 1990-2019, International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Nandhra S, Benson RA, Vascular and Endovascular Research Network VERN COVER Study Collaborative, 2022, The persistent challenges faced by vascular surgery services during the UK coronavirus pandemic: a snapshot qualitative survey, Annals of the Royal College of Surgeons of England, Vol: 104, Pages: 385-388, ISSN: 0035-8843
INTRODUCTION: The coronavirus (COVID-19) pandemic continues to affect the NHS. The Vascular and Endovascular Research Network (VERN) COvid Vascular sERvice (COVER) study has prospectively shown the significant global impact of the COVID-19 pandemic on vascular surgery. The aim of this study is to investigate the way in which this second wave has affected surgeons' ability to treat patients with urgent vascular conditions, using contemporaneous snapshot data from 30 UK vascular centres. METHODS: This is a contemporary (18-28 January 2021) re-run of the Tier 1 COVER survey. This used closed and open questions, related to centres' provision of common vascular services, threshold for treatment, imaging, screening, staff and theatre availability, multidisciplinary team input, clinics, personal protective equipment, vaccination policies and case-backlogs. The survey was disseminated to clinicians via email. A service reduction score was calculated. RESULTS: Forty-two complete responses were received from 30 vascular centres (England, Northern Ireland, Scotland and Wales). Overall, 56.7% of units are performing only urgent procedures. The threshold for abdominal aortic aneurysm (AAA) repair has increased in the majority of UK centres (60%). One in six AAA screening programmes have stopped all screening activity: 30% having a significantly reduced programme and only half running as normal. Waiting lists are increasing for AAA, lower limb revascularisation and venous disease. CONCLUSION: Overall, these data suggest that vascular care in the NHS is facing unprecedented pressures due to COVID-19. Vascular stakeholders will have to urgently address these issues in the coming months. STUDY REGISTRATION NUMBER: ISRCTN 80453162 (registered prospectively).
Taha M, Busuttil A, Bootun R, et al., 2022, Clinical outcomes and overview of dedicated venous stents for management of chronic iliocaval and femoral deep venous disease, Vascular, Vol: 30, Pages: 320-330, ISSN: 0967-2109
ObjectivesVenous stenting of the lower extremities has grown in popularity and is now considered a key component of the primary treatment strategy for the management of pathologically obstructive or stenotic lesions of the deep venous system. This review aims to provide an overview of the role of venous stenting in the management of chronic conditions affecting the deep venous system of the lower limbs.MethodsAn overview of venous stents design and current role of stenting procedure in individuals presenting with Chronic Venous Insufficiency (CVI) and presenting the current trials of dedicated venous stenting in management of chronic deep venous lesions. This review provides a focused insight on venous stent design, physical properties and the available dedicated venous stents selected studies with their related patency outcome based on selective literature search of the PubMed database and Cochrane library.ConclusionsDedicated venous stent technology is advancing at a rapid pace alongside the increased undertaking of endovascular deep venous stent reconstruction in the management of iliocaval vein pathologies. The ideal design(s) for venous stents remain unknown, although it is hoped that the presence of new dedicated venous stents in clinical practice will allow the generation of experience and data to advance our understanding in this area.
Essa M, Ghajar A, Delago A, et al., 2022, Demographic and state-level trends in mortality due to ischemic heart disease in the United States frmo 1999-2019, American Journal of Cardiology, Vol: 144, ISSN: 0002-9149
Although there have been advances in ischemic heart disease (IHD) care, variation in IHD-related mortality trends across the United States has not been well described. We used the CDC-WONDER database to evaluate variation in IHD-related mortality for demographic groups in the U.S. between 1999 and 2019. Age-adjusted mortality rates (AAMR) were stratified by sex, race, Hispanic ethnicity, and U.S. state. Crude mortality rates were evaluated using 10-year age groups. IHD-related AAMR decreased from 195 to 88 per 100,000 nationally, with slower decline from 2010-2019 (average annual percent change [AAPC] -2.6% [95% CI -2.9% to -2.2%) compared to 2002-2010 (AAPC -5.3% [95% CI -5.6% to -4.9%]). All groups had decreases in AAMR, though black populations persistently had the highest AAMR, and women had greater relative decreases than men. AAPC was -3.7% for white men; -4.7% for white women; -3.9% for black men; -4.9% for black women; -4.1% for Hispanic men, and -5.1% for Hispanic women. Populations ≥65 years old had greater relative mortality declines compared to populations <65 years. The median AAMR (2019) and AAPC (1999-2019) across states was 86.3 (range 58 – 134) and -3.8% (range -1.7% to -4.8%), respectively. In conclusion, mortality declines due to IHD have slowed in the U.S., with significant geographic variation. Black populations persistently had the highest AAMR, and declines were relatively greater for women and populations ≥65 years. The impact of demographics and geography on IHD should be further explored and addressed as part of public health measures.
Eves J, Sudarsanam A, Shalhoub J, et al., 2022, 320Augmented Reality in Vascular and Endovascular Surgery: A Scoping Review, ASiT Surgical Innovation Summit - Future Surgery Show, Publisher: OXFORD UNIV PRESS, ISSN: 0007-1323
Gebran A, Gaitanidis A, Argandykov D, et al., 2022, Mortality & pulmonary complications in emergency general surgery patients with mortality COVID-19, Journal of Trauma and Acute Care Surgery, Vol: 93, Pages: 59-65, ISSN: 2163-0755
Objectives The outcomes of emergency general surgery (EGS) patients with concomitant COVID-19 infection remain unknown. With a multicenter study in 361 hospitals from 52 countries, we sought to study the mortality and pulmonary complications of COVID-19 patients undergoing EGS.Methods All patients aged ≥17 years and diagnosed preoperatively with COVID-19 between February and July 2020 were included. EGS was defined as the urgent/emergent performance of appendectomy, cholecystectomy, or laparotomy. The main outcomes were 30-day mortality and 30-day pulmonary complications (a composite of acute respiratory distress syndrome, unexpected mechanical ventilation, pneumonia). Planned subgroup analyses were performed based on presence of preoperative COVID-related respiratory findings (e.g. cough, dyspnea, need for oxygen therapy, chest radiology abnormality).Results A total of 1,045 patients were included, of which 40.1% were female and 50.0% were older than 50 years; 461 (44.1%), 145 (13.9%), and 439 (42.0%) underwent appendectomy, cholecystectomy, and laparotomy, respectively. The overall mortality rate was 15.1% (158/1,045) and the overall pulmonary complication rate was 32.9% (344/1,045); in the subgroup of laparotomy patients, the rates were 30.6% (134/438) and 59.2% (260/439), respectively. Subgroup analyses found mortality and pulmonary complication risk to be especially increased in patients with preoperative respiratory findings.Conclusion COVID-19 patients undergoing EGS have significantly high rates of mortality and pulmonary complications, but the risk is most pronounced in those with preoperative respiratory findings.Level of Evidence Level III
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.